CV2 Antibody, IgG by CBA-IFA With Reflex to Titer, CSF
Ordering Recommendation
Consider ordering for individuals with paraneoplastic encephalomyelitis, chorea, cerebellar degeneration, optic neuritis, and peripheral neuropathy. May aid in diagnosis of occult or recurrent tumor. Serum is the preferred specimen.
New York DOH Approval Status
Specimen Required
CSF.
Transfer 0.5 mL CSF to an ARUP standard transport tube. (Min: 0.15 mL)
Refrigerated.
Hemolyzed, contaminated, or severely lipemic specimens.
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month
Methodology
Semi-Quantitative Cell-Based Indirect Fluorescent Antibody
Performed
Thu
Reported
1-8 days
Reference Interval
Test Number |
Components |
Reference Interval |
---|---|---|
CV2 Ab IgG CBA-IFA Screen, CSF | Less than 1:1 |
Interpretive Data
CV2 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2 is associated with small-cell lung cancer and thymoma. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.
This indirect fluorescent antibody assay utilizes CV2 transfected cell lines for the detection and semiquantification of the CV2 IgG antibody.
Laboratory Developed Test (LDT)
Note
If CV2 Antibody IgG Screen by IFA, CSF is positive, then CV2 Antibody IgG Titer, CSF will be added. Additional charges apply.
Hotline History
Hotline History
CPT Codes
86255; if reflexed, add 86256
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
3002259 | CV2 Ab IgG CBA-IFA Screen, CSF | 53707-6 |
Aliases
- Cerebellar degeneration
- Chorea
- Collapsin response-mediator protein 5
- Cranial neuropathy
- CRMP5
- CV2
- Myelopathy
- Peripheral neuropathy
- Vision loss